Q3 Earnings Forecast for MRVI Issued By KeyCorp

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) – Investment analysts at KeyCorp issued their Q3 2027 earnings per share estimates for shares of Maravai LifeSciences in a report issued on Wednesday, November 11th. KeyCorp analyst P. Knight forecasts that the company will post earnings per share of ($0.05) for the quarter. KeyCorp has an “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Maravai LifeSciences’ current full-year earnings is ($0.16) per share.

A number of other research firms have also recently weighed in on MRVI. UBS Group raised their price target on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. TD Cowen initiated coverage on shares of Maravai LifeSciences in a research note on Monday, October 5th. They set a “buy” rating and a $9.00 price objective for the company. Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. Finally, Wells Fargo & Company raised their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Maravai LifeSciences has an average rating of “Moderate Buy” and an average price target of $8.10.

Get Our Latest Report on Maravai LifeSciences

Maravai LifeSciences Stock Performance

Shares of NASDAQ MRVI opened at $7.54 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.66 and a quick ratio of 3.35. The stock has a market capitalization of $1.96 billion, a P/E ratio of -17.53 and a beta of 0.61. Maravai LifeSciences has a 1-year low of $2.80 and a 1-year high of $9.42. The business has a fifty day moving average price of $7.40 and a 200 day moving average price of $5.43.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $45.85 million for the quarter, compared to the consensus estimate of $43.56 million. Maravai LifeSciences had a negative return on equity of 12.44% and a negative net margin of 30.83%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP increased its position in Maravai LifeSciences by 38.2% during the 3rd quarter. Marshall Wace LLP now owns 2,034,070 shares of the company’s stock valued at $15,581,000 after buying an additional 562,593 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Maravai LifeSciences by 0.9% in the first quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock worth $12,069,000 after acquiring an additional 39,600 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Maravai LifeSciences in the third quarter worth about $5,259,000. Dimensional Fund Advisors LP boosted its holdings in Maravai LifeSciences by 64.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock worth $4,015,000 after acquiring an additional 558,050 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Maravai LifeSciences during the second quarter worth about $2,230,000. 50.25% of the stock is owned by institutional investors and hedge funds.

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.

Read More

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.